Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection

被引:40
|
作者
Forsyth, Valerie S. [1 ]
Himpsl, Stephanie D. [1 ]
Smith, Sara N. [1 ]
Sarkissian, Christina A. [1 ,3 ]
Mike, Laura A. [1 ]
Stocki, Jolie A. [1 ]
Sintsova, Anna [1 ,4 ]
Alteri, Christopher J. [1 ,2 ]
Mobley, Harry L. T. [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Nat Sci, Dearborn, MI 48128 USA
[3] Arbor Biosci, Ann Arbor, MI USA
[4] Univ Zurich, Zurich, Switzerland
来源
MBIO | 2020年 / 11卷 / 02期
基金
美国国家卫生研究院;
关键词
CpG; Escherichia coli; FyuA; Hma; IreA; IutA; MPLA; vaccine; alum; dmLT; polyIC; urinary tract infection; MONOPHOSPHORYL-LIPID-A; T-CELL RESPONSES; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; MURINE MODEL; MUCOSAL; IMMUNIZATION; ADJUVANT; EFFICACY; RECEPTOR;
D O I
10.1128/mBio.00555-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Urinary tract infections (UTI) affect half of all women at least once during their lifetime. The rise in the numbers of extended-spectrum beta-lactamase-producing strains and the potential for carbapenem resistance within uropathogenic Escherichia coli (UPEC), the most common causative agent of UTI, create an urgent need for vaccine development. Intranasal immunization of mice with UPEC outer membrane iron receptors FyuA, Hma, IreA, and lutA, conjugated to cholera toxin, provides protection in the bladder or kidneys under conditions of challenge with UPEC strain CFT073 or strain 536. On the basis of these data, we sought to optimize the vaccination route (intramuscular, intranasal, or subcutaneous) in combination with adjuvants suitable for human use, including aluminum hydroxide gel (alum), monophosphoryl lipid A (MPLA), unmethylated CpG synthetic oligodeoxynucleotides (CpG), polyinosinic:polycytidylic acid (polyIC), and mutated heat-labile E. coil enterotoxin (dmLT). Mice intranasally vaccinated with dmLT-lutA and dmLT-Hma displayed significant reductions in bladder colonization (86-fold and 32-fold, respectively), with 40% to 42% of mice having no detectable CFU. Intranasal vaccination of mice with CpG-lutA and polyIC-lutA significantly reduced kidney colonization (131-fold) and urine CFU (22-fold), respectively. dmLT generated the most consistently robust antibody response in intranasally immunized mice, while MPLA and alum produced greater concentrations of antigen-specific serum IgG with intramuscular immunization. On the basis of these results, we conclude that intranasal administration of Hma or lutA formulated with dmLT adjuvant provides the greatest protection from UPEC UTI. This report advances our progress toward a vaccine against uncomplicated UTI, which will significantly improve the quality of life for women burdened by recurrent UTI and enable better antibiotic stewardship. IMPORTANCE Urinary tract infections (UTI) are among the most common bacterial infection in humans, affecting half of all women at least once during their lifetimes. The rise in antibiotic resistance and health care costs emphasizes the need to develop a vaccine against the most common UTI pathogen, Escherichia coli. Vaccinating mice intranasally with a detoxified heat-labile enterotoxin and two surface-exposed receptors, Hma or lutA, significantly reduced bacterial burden in the bladder. This work highlights progress in the development of a UTI vaccine formulated with adjuvants suitable for human use and antigens that encode outer membrane iron receptors required for infection in the iron-limited urinary tract.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection
    Killgore, KM
    March, KL
    Guglielmo, BJ
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) : 1148 - 1152
  • [42] Presence of urinary symptoms in bacteremic urinary tract infection: a retrospective cohort study of Escherichia coli bacteremia
    Anthony D. Bai
    Michael J. Bonares
    Samuel Thrall
    Chaim M. Bell
    Andrew M. Morris
    BMC Infectious Diseases, 20
  • [43] In vivo detection of Escherichia coli type 1 fimbrial expression and phase variation during experimental urinary tract infection
    Struve, C
    Krogfelt, KA
    MICROBIOLOGY-SGM, 1999, 145 : 2683 - 2690
  • [44] Diarrheagenic enteroaggregative Escherichia coli causing urinary tract infection and bacteremia leading to sepsis
    K. Herzog
    J. Engeler Dusel
    M. Hugentobler
    L. Beutin
    G. Sägesser
    R. Stephan
    H. Hächler
    M. Nüesch-Inderbinen
    Infection, 2014, 42 : 441 - 444
  • [45] Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries
    N. L. Ramos
    D. T. N. Dzung
    K. Stopsack
    V. Jankó
    M. R. Pourshafie
    M. Katouli
    A. Brauner
    European Journal of Clinical Microbiology & Infectious Diseases, 2011, 30 : 1587 - 1593
  • [46] Evaluating the prevalence of virulence genes of Escherichia coli in patients affected by urinary tract infection
    Kakian, Farshad
    Abadi, Milad Shahini Shams
    Gholipour, Abolfazl
    Fadaie, Maryam
    Zamanzad, Behnam
    Khairi, Soliman
    Parchami, Shahrbano
    Damavandi, Mohamad Sadegh
    GENE REPORTS, 2019, 16
  • [47] A shear stress micromodel of urinary tract infection by the Escherichia coli producing Dr adhesin
    Zalewska-Piatek, Beata
    Olszewski, Marcin
    Lipniacki, Tomasz
    Blonski, Slawomir
    Wieczor, Milosz
    Bruzdziak, Piotr
    Skwarska, Anna
    Nowicki, Bogdan
    Nowicki, Stella
    Piatek, Rafal
    PLOS PATHOGENS, 2020, 16 (01)
  • [48] Blocking Yersiniabactin Import Attenuates Extraintestinal Pathogenic Escherichia coli in Cystitis and Pyelonephritis and Represents a Novel Target To Prevent Urinary Tract Infection
    Brumbaugh, Ariel R.
    Smith, Sara N.
    Subashchandrabose, Sargurunathan
    Himpsl, Stephanie D.
    Hazen, Tracy H.
    Rasko, David A.
    Mobley, Harry L. T.
    INFECTION AND IMMUNITY, 2015, 83 (04) : 1443 - 1450
  • [49] Innate immunity of surfactant proteins A and D in urinary tract infection with uropathogenic Escherichia coli
    Hu, Fengqi
    Ding, Guohua
    Zhang, Zhiyong
    Gatto, Louis A.
    Hawgood, Samuel
    Poulain, Francis R.
    Cooney, Robert N.
    Wang, Guirong
    INNATE IMMUNITY, 2016, 22 (01) : 9 - 20
  • [50] Recurrent Guillain-Barre Syndrome Following Urinary Tract Infection by Escherichia coli
    Jo, Yoon-Sik
    Choi, Jin-Yong
    Chung, Hong
    Kim, Yuseok
    Na, Sang-Jun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (04)